In a recent prospective study, it was observed that patients affected by severe COVID-19 and treated with anakinra alone or in combination with tocilizumab subsequently did not have an altered antibody response [4]; another study investigating the effect of vaccination on autoinflammatory diseases showed that the anti-SARS-CoV-2 vaccine was well tolerated in patients with pathologies mediated by IL-1, IL-18, and interferon (IFN)-γ, with no disease relapses requiring hospitalization, and presenting an adequate antibody production after the booster dose [5]. The gene discussed is IL1B; the disease is COVID-19.